10x Genomics (TXG) to Release Earnings on Tuesday

10x Genomics (NASDAQ:TXG) will release its earnings data after the market closes on Tuesday, April 30th. Analysts expect 10x Genomics to post earnings of ($0.46) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

10x Genomics (NASDAQ:TXG) last released its quarterly earnings data on Thursday, February 15th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.05). The company had revenue of $183.98 million for the quarter, compared to the consensus estimate of $182.73 million. 10x Genomics had a negative return on equity of 28.82% and a negative net margin of 41.17%. The business’s revenue was up 17.8% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.15) earnings per share. On average, analysts expect 10x Genomics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

10x Genomics Stock Down 0.5 %

TXG opened at $27.80 on Tuesday. The business has a fifty day simple moving average of $39.34 and a 200-day simple moving average of $42.89. The firm has a market cap of $3.31 billion, a PE ratio of -12.81 and a beta of 1.90. 10x Genomics has a fifty-two week low of $26.75 and a fifty-two week high of $63.57.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Stifel Nicolaus reduced their target price on 10x Genomics from $68.00 to $63.00 and set a “buy” rating for the company in a report on Friday, February 16th. Deutsche Bank Aktiengesellschaft reduced their target price on 10x Genomics from $60.00 to $55.00 and set a “buy” rating for the company in a report on Thursday, April 18th. Finally, Barclays cut their price objective on 10x Genomics from $55.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday, April 10th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.22.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 1,000 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $49.53, for a total transaction of $49,530.00. Following the transaction, the chief executive officer now directly owns 855,381 shares of the company’s stock, valued at $42,367,020.93. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, CFO Justin J. Mcanear sold 1,865 shares of the firm’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $46.34, for a total value of $86,424.10. Following the sale, the chief financial officer now directly owns 95,240 shares of the company’s stock, valued at $4,413,421.60. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Serge Saxonov sold 1,000 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $49.53, for a total value of $49,530.00. Following the completion of the sale, the chief executive officer now directly owns 855,381 shares in the company, valued at $42,367,020.93. The disclosure for this sale can be found here. Insiders have sold 12,959 shares of company stock valued at $592,806 over the last three months. 10.65% of the stock is currently owned by insiders.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.